- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05998343
Intergenerational Program for Social Isolation and Loneliness in Older Adults Discharged From the Emergency Department (SIL)
Improving Social Isolation and Loneliness in Older Adults Discharged From the Emergency Department - Comparing an Intergenerational Versus Same Generation Peer-support Intervention Versus Common Wait List Control Group in a Three Arm RCT
Social isolation and loneliness worsens older adults' risk of dementia, quality of life, and death as much as smoking. Older adults are more likely to use emergency services and are also more likely to experience social isolation and loneliness than younger people. The emergency department is a new setting to screen for social isolation and loneliness in older adults and help accordingly.
Social isolation and loneliness are experienced differently by different older adults. Different interventions combatting social isolation and loneliness may work better for different people, and little is known about older adult's preferences for specific types of interventions.
HOW R U? is an effective and feasible intervention using same-generation peer support offered by trained hospital volunteers to reduce social isolation and loneliness in older adults. In partnership with the Australian developer of HOW R U?, this study will compare an intergenerational HOW R U? intervention using younger volunteers with the same-generation peer support intervention and a waitlist control arm.
The investigators partnered with the staff of emergency departments and family medicine clinics to identify people who will benefit from an intervention combatting, and Volunteer Services to recruit volunteers.
The investigators hypothesize that the older adults who receive the intergenerational HOW R U? intervention will have a greater improvement in social isolation and loneliness.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction:
Social isolation and loneliness (SIL) worsens mortality and other outcomes among older adults as much as smoking. The investigators previously tested the impact of the HOW R U? intervention using peer support from similar aged volunteers and demonstrated reduced SIL among older adults discharged from the Emergency Department (ED). Generativity, defined as "the interest in establishing and guiding the next generation" can provide an alternative theoretical basis for reducing SIL via intergenerational programs between members of younger and older generations. The current study will examine the impact of younger intergenerational volunteers providing the HOW R U? intervention. As part of a program of research following the Obesity-Related Behavioral Intervention Trials (ORBIT ) model, findings of this RCT will be used to define which intervention characteristics are most effective in reducing SIL. This trial builds on feasibility work conducted in the investigators' previous trial (NCT 05228782).
Methods and Analysis:
The investigators will compare the use of the same-generation peer support HOW RU? intervention to support by intergenerational volunteers. The investigators will use a common wait list control group in this three-arm randomized controlled trial (RCT).
Trained volunteers will deliver 12 weekly telephone support calls. The investigators will recruit 141 participants ≥70 years of age with baseline loneliness (six-item De Jong loneliness score of 2 or greater) from two EDs. Research staff will assess change in loneliness (De Jong Loneliness Scale), social isolation (Lubben's Social Network Scale), depression (Geriatric Depression Score), quality of life (EQ-5D-5L), functional status (Older Americans Resource Scale), generativity (Loyola Generativity Scale), and perceived benefit at baseline (subjective Likert scale), at 12-14 weeks, and 24-26 weeks post-intervention. The study will follow the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.
Ethics and Dissemination:
The participating research ethics boards have granted ethics approval, and the participants randomized to the waitlist control group will be offered their choice of intergenerational or same-generation HOW R U? interventions after 12 weeks. Results will be shared through journal publications, conference presentations, social media, and through the International Federation of Emergency Medicine.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jacques Lee, MD
- Phone Number: 4168771447
- Email: Jacques.lee@sinaihealth.ca
Study Contact Backup
- Name: David Zheng, MD
- Phone Number: 5199335838
- Email: dzheng33@uwo.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1XS
- Recruiting
- Mount Sinai Hospital
-
Contact:
- Jacques Lee, MD
- Email: Jacques.lee@sinaihealth.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any community-dwelling person 70 years of age and older receiving care from the ED, Family Medicine, or Geriatric clinics at the two participating sites (MSH and NYGH) will be eligible.
- Baseline de Jong loneliness scores of 2.0 will be required for participation in the trial.
Exclusion Criteria:
- Age less than 70 years;
- Patients with communication problems (critically ill, unconscious, language barrier, speech impairment or otherwise unable to provide consent), or admission to a hospital for > 72 hours.
- Patients with severe cognitive impairment or those living in nursing homes who are dependent on others for their activity of daily living will be excluded.
- Patients without any mobile phone or landline.
Volunteers:
- Volunteers will be 60 years of age or older to qualify as peer-support volunteers.
- Volunteers will be 19-39 years of age to qualify as intergenerational volunteers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HOW R U? intervention delivered by same-generation peer volunteer
HOW R U?
|
1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
|
Experimental: HOW R U? intervention delivered by intergenerational volunteer
|
1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.
|
No Intervention: Waitlist control group
After the primary outcome assessment at 12 weeks, control group participants will be offered HOW R U? intervention support outside of the main trial.
They will be allowed to choose either intergenerational or same-generation versions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in loneliness using De Jong Gierveld 6-item Loneliness Scale from Baseline to 12 Weeks
Time Frame: Measure at baseline, at 12 weeks (primary outcome) and 24 weeks (sustainability)
|
The minimum value is 0 and the maximum value is 6, with the higher value corresponding with a greater degree of loneliness.
It is divided into 4 clinically relevant categories: 0-1 = no loneliness, 2-3 = low levels of loneliness, 4-5 = moderate to severe loneliness, and 6 = severe loneliness.
|
Measure at baseline, at 12 weeks (primary outcome) and 24 weeks (sustainability)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in perceived social support using Lubben Social Network Scale
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
The Lubben Social Network Scale is a measure of perceived social support received from the family and friends and consists of 6 items each of which is scored from 0 to 5: none = 0, one = 1, two = 2, three or four = 3, five through eight = 4, nine or more = 5.
The total score ranges from 0 to 30, and a score of 12 and lower indicates a status of "at-risk" for social isolation
|
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Change in mood using Geriatric Depression Scale
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
The Geriatric Depression Scale is a 15-item scale of mood that is extensively validated in older populations to screen for depression.
Scores range from 0 to 15.
A score of 0-4 is considered normal, and a score of 5 or higher is considered indicative of depression with higher scores indicating higher severity of depression.
|
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Change in Quality of Life using Euro-Qual 5 Dimensions 5 Levels
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
EQ-5D-5Lin 5 dimensions.
In each dimension, quality of life can be measured from 1 (best quality of life) to 5 (worst quality of life), giving a possible score of 5-25.
A higher score indicates worse quality of life.
(Euro-Qual 5 Dimensions 5 Levels) scale assesses quality of life
|
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Change in Functional Status using Older Americans Resource Scale
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
The Older Americans Resource Scale (OARS) consists of 7 activities of daily living (ADL) questions and 7 instrumental activities of daily living (IADL) all rated as "without any help" (2 points), "with some help" (1 point), or "completely unable" (0 points).
The ADL and IADL scores can be used separately or combined to produce an overall OARS score from 0-28.
|
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Change in self-perceptions of generativity using Loyola Generativity Scale
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
The Loyola Generativity Scale is a 20-item scale with each question answered 0 = statement never applies to you, 1 = statement only occasionally or seldom applies to you, 2 = statement applies to you fairly often, or 3 = statement applies to you very often or nearly always. The higher the score, the greater the sense of generativity. |
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Perceived benefit to participant at 12 weeks
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Perceived benefit by the participant pre- and post-intervention will be assessed using the question "Compared to working with a volunteer around the same age as you, you think that working with a younger volunteer is:" followed by a 5-point Likert scale with the following options: A lot less helpful for me, a little less helpful for me, about the same for me, a little more helpful for me, or a lot more helpful for me.
|
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Perceived benefit to volunteer at 12 weeks
Time Frame: Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Perceived benefit by the participant for the volunteer pre- and post-intervention will be assessed using the question "Compared to working with a volunteer around the same age as you, you think that working with a younger volunteer is:" followed by a 5-point Likert scale with the following options: A lot less helpful for the volunteer, a little less helpful for the volunteer, about the same for the volunteer, a little more helpful for the volunteer, or a lot more helpful for volunteer.
|
Measure at baseline, at 12 weeks and 24 weeks (sustainability)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility and Process Outcome 1 - Participant preference
Time Frame: Measure at 12 weeks
|
To assess for participant preference for same-generation peer support versus intergenerational HOW R U? intervention, we will use a 5-point Likert scale with the following options: "I strongly prefer peer support", "I prefer peer support", "neutral", "I prefer intergenerational" and "I strongly prefer intergenerational".
|
Measure at 12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-0074-E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Loneliness
-
University of RochesterNational Institute on Aging (NIA)Recruiting
-
Vladimíra DostálováBarcelona Institute for Global HealthRecruiting
-
Taipei Medical UniversityCompleted
-
Linkoeping UniversityUniversity College, LondonCompleted
-
KTO Karatay UniversityCompleted
-
Florida State UniversityCompleted
-
Heartfulness InstituteCompletedLonelinessUnited States
-
Trustees of Dartmouth CollegeRecruiting
-
University of OregonNational Institute on Drug Abuse (NIDA); HopeLab FoundationCompleted
Clinical Trials on Same-Generation Peer Support HOW R U?
-
Mount Sinai Hospital, CanadaKing's College London; University of Toronto; Sunnybrook Research Institute; North... and other collaboratorsRecruitingLoneliness | Geriatric | Social IsolationCanada
-
Children's Oncology GroupNational Cancer Institute (NCI); EsPhALL Network/ BFM Study GroupRecruitingAcute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute LeukemiaUnited States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States